Skip to main content
. 2024 Oct 18;17(11):sfae309. doi: 10.1093/ckj/sfae309

Figure 2:

Figure 2:

Cumulative incidence of breakthrough COVID-19 in the tixagevimab–cilgavimab and control groups over 6-month follow-up.